Literature DB >> 2527553

On the diagnosis of erythrocyte enzyme defects in the presence of high reticulocyte counts.

M Lakomek1, W Schröter, G De Maeyer, H Winkler.   

Abstract

The separation of red blood cells into reticulocytes and young and old erythrocytes enables investigations of fractions with different contents of reticulocytes. Activities of hexokinase, glucose phosphate isomerase, phosphofructokinase, pyruvate kinase and glucose-6-phosphate dehydrogenase showed a linear relationship to reticulocyte counts. The dependence of these enzyme activities on the age of the red blood cells exhibited a strong decline from the reticulocyte to the young erythrocyte stage followed by only little further loss of activity, thus leading to a biphasic decay of enzyme activities. By linear regression analysis enzyme activities in erythrocytes (AE) and reticulocytes (AR) could be evaluated. The activity of a given enzyme in the reticulocyte exceeded that of the erythrocyte; the quotient AR/AE represents the decline of enzyme activity from the reticulocyte to the erythrocyte stage. This value AR/AE is 16.7 for pyruvate kinase and 9.4 for hexokinase and thus considerably higher than that for the other enzymes investigated (glucose phosphate isomerase: 2.9, phosphofructokinase: 4.3, glucose-6-phosphate dehydrogenase: 4.5). In patients suffering from erythrocyte enzymopathies, the AR/AE for pyruvate kinase was 16.2 and thus almost identical to the normal enzyme. Calibration curves where the enzyme activity is plotted versus the fraction of reticulocytes enable the determination of normal activity of a given erythrocyte enzyme depending on the content of reticulocytes in red blood cell suspensions. Thus an unambiguous diagnosis of enzyme defects irrespective of reticulocyte counts becomes possible.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527553     DOI: 10.1111/j.1365-2141.1989.tb07730.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  An Ashkenazi Jewish woman presenting with favism.

Authors:  F Lim; T Vulliamy; S H Abdalla
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

2.  Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency.

Authors:  Paola Bianchi; Elisa Fermo; Bertil Glader; Hitoshi Kanno; Archana Agarwal; Wilma Barcellini; Stefan Eber; James D Hoyer; David J Kuter; Tabita Magalhães Maia; Maria Del Mar Mañu-Pereira; Theodosia A Kalfa; Serge Pissard; José-Carlos Segovia; Eduard van Beers; Patrick G Gallagher; David C Rees; Richard van Wijk
Journal:  Am J Hematol       Date:  2018-11-28       Impact factor: 10.047

3.  Mutations in the R-type pyruvate kinase gene and altered enzyme kinetic properties in patients with hemolytic anemia due to pyruvate kinase deficiency.

Authors:  M Lakomek; P Huppke; B Neubauer; A Pekrun; H Winkler; W Schröter
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

4.  Incorporating G6PD genotyping to identify patients with G6PD deficiency.

Authors:  Sarah A Morris; Kristine R Crews; Randall T Hayden; Clifford M Takemoto; Wenjian Yang; Donald K Baker; Ulrich Broeckel; Mary V Relling; Cyrine E Haidar
Journal:  Pharmacogenet Genomics       Date:  2022-04-01       Impact factor: 2.089

5.  Diagnostic performances of the fluorescent spot test for G6PD deficiency in newborns along the Thailand-Myanmar border: A cohort study.

Authors:  Laurence Thielemans; Gornpan Gornsawun; Borimas Hanboonkunupakarn; Moo Kho Paw; Pen Porn; Paw Khu Moo; Bart Van Overmeire; Stephane Proux; François Nosten; Rose McGready; Verena I Carrara; Germana Bancone
Journal:  Wellcome Open Res       Date:  2018-01-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.